Clinical trials: Peritoneum Cancer
Ovarian, Fallopian Tube and Peritoneal Cancer
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a phase-I, dose escalation study to assess the safety and biological activity of cyclophosphamide/fludarabine lymphodepletion followed by adoptive transfer of vaccine-primed, ex vivo CD3/CD28-costimulated peripheral blood…
- Trial name
- NCT02277392
- Testing
- Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells, SB---485232 (Human recombinant Interleukin---18)
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Fallopian Tube Cancer, Ovarian Cancer
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT01402271
- Testing
- carboplatin, paclitaxel, pazopanib hydrochloride
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 88 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastric Adenocarcinoma, Gastric Cancer
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Background: Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
- Trial name
- NCT04034251
- Testing
- Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT01137071
- Testing
- Monoclonal antibody Hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 29 people
- Sponsor
- Recepta Biopharma
Stage IV Gastric Cancer
S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis
This study is designed to investigate the efficacy of S-1 plus cisplatin hyperthermic intraperitoneal chemotherapy for advanced gastric patients of gastric cytoreductive surgery (CRS)
- Trial name
- NCT02291211
- Testing
- S-1 plus cisplatin HIPEC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Cancer
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
The purpose of this study is to find out if postoperative chemotherapy in patients with high-grade appendix cancer after surgery improves outcomes.
- Trial name
- NCT02420509
- Testing
- systemic chemotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Diego
Advanced Gastric Cancer, Advanced Colorectal Cancer
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
The goal of this clinical trial is to see if high- and low-dose radiotherapy combined with immunotherapy can work in patients with advanced gastric, colorectal, and ovarian cancers with peritoneal metastases, and to learn about…
- Conditions
- Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal Metastasis
- Trial name
- NCT06940921
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Zhang Tao
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
- Trial name
- NCT04095364
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 909 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- NRG Oncology
Gastric Cancer
HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis
To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
- Trial name
- NCT05648487
- Testing
- HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
- Volunteers
- 46 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC.
- Conditions
- Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02033616
- Testing
- AVOVA-1, MC
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aivita Biomedical, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- OVATION 2 (NCT03393884)
- Testing
- IMNN-001, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Imunon
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product.
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT05617755
- Testing
- AB-1015
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Arsenal Biosciences, Inc.
Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy.
- Conditions
- Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma
- Trial name
- NCT01080521
- Testing
- Cognitive Assessment, Quality-of-Life Assessment
- Where
- 182 sites in United States
- Volunteers
- 247 people
- Sponsor
- Gynecologic Oncology Group
Malignant Neoplasms of Female Genital Organs, Ovarian Cancer
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery.
- Conditions
- Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02884648
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Ovarian Cancer
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
- Trial name
- ROLANDO (NCT03161132)
- Testing
- Olaparib, Pegylated Liposomal Doxorubicin
- Where
- 8 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer, Primary Peritoneal Serous Cancer
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
The purpose of this study is to evaluate how the participant's disease (ovarian, primary peritoneal serous, fallopian tube, or papillary serous endometrial cancer) responds to additional treatment with Avastin (bevacizumab).
- Conditions
- Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
- Trial name
- NCT00866723
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer.
- Conditions
- Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7, Stage I Fallopian Tube Cancer AJCC v6 and v7, Stage I Ovarian Cancer AJCC v6 and v7
- Trial name
- NCT03902379
- Testing
- Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Peritoneal Carcinomatosis, Peritoneal Metastases
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase…
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer
- Trial name
- PIPAC-NAL-IRI (NCT05277766)
- Testing
- PIPAC with Nal-IRI
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Mesothelioma
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
In patients with pleural or peritoneal mesothelioma, what is the response rate to combined Oxaliplatin (ELOXATIN®) and Gemcitabine chemotherapy?
- Trial name
- NCT00859469
- Testing
- Oxaliplatin, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Columbia University
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)